Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001)

A promising approach for the treatment of genetic diseases is called gene therapy.

Locations

702 United States sites

Age

13 Years - 40 Years

Phase

Phase 2

LEARN MORE
A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants With Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants With Sickle Cell Disease

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

Locations

1184 United States sites

179 Nigeria sites

60 Kenya sites

46 Lebanon sites

Age

6 Months - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.

Locations

1638 United States sites

1039 India sites

442 United Kingdom sites

325 Canada sites

308 Italy sites

256 Turkey sites

232 Greece sites

181 France site

177 Spain sites

88 South Africa sites

33 Lebanon sites

4 Switzerland sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult and adolescent participants with severe sickle cell disease (SCD).

Locations

1437 United States sites

228 Canada sites

Age

12 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models [PREMIER]

This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.

Locations

267 United States sites

Age

18 Years - 65 Years

LEARN MORE
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)

This registry is an observational study designed to evaluate the effect of Oxbryta in individuals with SCD in a real-world setting.

Locations

1970 United States sites

Age

> 4 Years

LEARN MORE
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain

The investigators will conduct a hybrid type 1 effectiveness implementation trial to assess the effectiveness of acupuncture and guided relaxation on 360 people with Sickle Cell Disease (SCD), while observing and gathering information on implementation in three health systems: University of Illinois Hospital & Health Sciences System, University of Florida Health, and Duke University Health Systems.

Locations

306 United States sites

Age

> 18 Years

Phase

Phase 2

LEARN MORE
A Pilot Study of Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants.

Locations

145 United States sites

Age

> 18 Years

Phase

Phase 1/Phase 2

LEARN MORE
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app).

Locations

159 United States sites

Age

12 Years - 21 Years

Phase

Not Applicable

LEARN MORE
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients.

Locations

324 United States sites

Age

5 Years - 50 Years

LEARN MORE